Tel Aviv University

Merck Serono S. A.

Phenex Pharmaceuticals Ag

Biofrontera Discovery Gmbh

Merz Pharma Gmbh & Co Kgaa

Santhera Pharmaceuticals (schweiz) Ag

Zentopharm Gmbh

Ulrich Abel

Holger Deppe

Andreas Goutopoulos

Meinolf Thiemann

Matthias Schwarz

Xuliang Jiang

Werner Simon

Ehud Gazit

Achim Feurer

Renate Sekul

Kerstin Otte

Ulrich Grädler

Claus Kremoser

Ludmila Buzhansky

Yaniv Amir

Anat Frydman-Marom

Christoph Steeneck

Olaf Kinzel

Andreas Krause

Ulrich Deuschle

Andreas Schulz

Ulrich Graedler

Cesare Mondadori

Inge Ott

Michael Soeberdt

Barbara Hoffmann-Enger

Philipp Weyermann

Hervé Siendt

Christian Rummey

Miroslav Terinek

Marco Henneböhle

Holger Herzner

Sonja Nordhoff

Günther Metz

The present invention relates to a process for depleting epoxide species in epoxy-crosslinked polysaccharide gel compositions. In addition, the present invention relates to crosslinked polysaccharide gel compositions made by said process and their use in cosmetic and therapeutic applications.

Process for depleting epoxide species in crosslinked polysaccharide gel compositions and compositions obtained thereby

Dipeptide analogs comprising a tryptophan (Trp) moiety coupled to a beta-sheet breaker moiety derived from alpha-aminoisobutyric acid (Aib) are disclosed. The dipeptide analogs exhibit an improved performance in inhibiting amyloid fibril formation, as compared to previously described dipeptides. Compositions containing the dipetide analogs and uses thereof in treating amyloid-associated diseases and disorders are also disclosed.

Dipeptide analogs for treating conditions associated with amyloid fibril formation

Substituted indole derivatives of formula (I) wherein the radicals have e.g. the following meaning:

Indole derivatives and process for their preparation

Substituted indole derivatives of formula (I) wherein the radicals have e. g. the following meaning: Ris hydrogen, &#x2014;C-alkyl, Ris hydrogen, &#x2014;C-alkyl or cycloC-alkyl; Ris OR Ris hydrogen or halogen, Ris hydrogen, &#x2014;C-alkyl Ris hydrogen, &#x2014;C-alkyl R is hydrogen or &#x2014;C-alkyl; X is a group &#x2014;C(O)CH&#x2014; or &#x2014;CH&#x2550;CH&#x2014;; Ris hydrogen are potent inhibitors of Abeta peptide polymerization and can be used for the treatment of e.g. Alzheimers disease or ocular disorders. 

Dipeptide analogs comprising a tryptophan (Trp) moiety coupled to a beta-sheet breaker moiety derived from alpha-aminoisobutyric acid (Aib) are disclosed. The dipeptide analogs exhibit an improved performance in inhibiting amyloid fibril formation, as compared to previously described dipeptides. Compositions containing the dipeptide analogs and uses thereof in treating amyloid-associated diseases and disorders are also disclosed.

The present invention relates to compounds of formula (1): where R, A, Q and Z are defined herein, or an enantiomer, diastereomer, tautomer, solvate, prodrug or pharmaceutical acceptable salt thereof. These compounds bind to the NR1H4 receptor (FXR) and act as agonists of the NR1H4 receptor (FXR). The invention further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds, and to a process for the synthesis of said compounds.

FXR (NR1H4) binding and activity modulating compounds

The invention provides novel, substituted 3-arylamino pyridine compounds pharmaceutically acceptable salts, solvates and prodrug compounds thereof, wherein W, R1, R2, R9, R10, R11, R12, R13, R14 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer, restenosis and inflammation. Also disclosed is the use of such compounds in the treatment of hyperproliferative diseases in mammals, especially humans, and pharmaceutical compositions containing such compounds.

3-arylamino pyridine derivatives

The invention relates to novel fredericamycin derivatives, to drugs containing said derivatives or the salts thereof, and to the use of the fredericamycin derivatives for treating diseases, especially cancer diseases.

Fredericamycin derivatives

The present invention relates to substituted imidazopyridine derivatives as melanocortin-4 receptor (MC-4R) modulators, in particular as melanocortin-4 receptor antagonists. The antagonists are useful for the treatment of disorders and diseases such as cancer cachexia, muscle wasting, anorexia, amytrophic lateral sclerosis (ALS), anxiety and depression.

Substituted imidazopyridine derivatives as melanocortin-4 receptor antagonists

The present invention relates to compounds which bind to the NR1H4 receptor (FXR) and act as agonists or partial agonists of the NR1H4 receptor (FXR). The invention further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds, and to a process for the synthesis of said compounds.

Heterocyclic FXR binding compounds

The invention provides novel, substituted 3-arylamino pyridine compounds (I) pharmaceutically acceptable salts, solvates and prodrug compounds thereof, wherein W, R1, R2, R9, R10, R11, R12, R13, R14 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer, restenosis and inflammation. Also disclosed is the use of such compounds in the treatment of hyperproliferative diseases in mammals, especially humans, and pharmaceutical compositions containing such compounds. 

The invention relates to novel fredericamycin derivatives, to medicaments containing these derivatives or salts thereof, and to the use of fredericamycin derivatives for treating diseases, particularly tumor diseases.

The invention relates to novel fredericamycin derivatives of general formula (Ia) or (Ib), to medicaments containing the fredericamycin derivatives or salts thereof, and to the use of the fredericamycin derivatives for treating diseases, especially tumor diseases. 

Growing community of inventors

Heidelberg, Germany

Ulrich Abel